Trial Profile

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 2463 (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Montanide ISA-51
Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Acronyms SIDNEY
Sponsors Enterome

21 Jul 2026 According to an Enterome media release, data from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2026.
21 Jul 2026 According to an Enterome media release, presented the data today at the Pan Pacific Lymphoma Conference (PPLC).
21 Jul 2026 Results presented in the Enterome media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com